Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

University of Utah Research Foundation

Enata Pharmacueticals, Inc.

Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Dennie S Welch

Albert Wayne Kruger

Stevan Wakefield Djuric

Wilfried Martin Braje

Sean Colm Turner

Yat Sun Or

Guoqiang Wang

Andrew J Souers

Philip R Kym

George A Doherty

Xilu Wang

Zhi-Fu Tao

Milan Bruncko

Aaron R Kunzer

Russell Drew Cink

Alan Frank Gasiecki

Kirill A Lukin

David R Hill

Shashank Shekhar

Noel S Wilson

Ana-Lucia Relo

Michael J Abrahamson

Yonghua Gai

Xueqing Wang

Gerard M Sullivan

Keith F McDaniel

Jason P Shanley

Jennifer M Frost

Xiaohong Song

Andrew S Judd

Jorge Gandarilla

Irini Akritopoulou-Zanze

Marvin Robert Leanna

Hongyu H Zhao

Jianzhang Mei

Min Zhang

Kenneth M Engstrom

Matthew M Ravn

Matthew J Pelc

Christina M Thompson

Brian E Green

Erwin R Boghaert

Gang Zhao

Timothy B Towne

Richard D Bishop

Westin H Morrill

Huanqiu Li

Jeff M Kallemeyn

Hui-Ju J Chen

Steven Cramer Cullen

Shuang Chen

Anh P Truong

Jonathan A Covel

Carina Cristina Sanchez

Gary E Keck

Matthew B Kraft

Wei Li

Yam Poudel

Jorge Gandarllla

Violeta L Marin

Zhaoming Xiong

Shashank Shekar

Scott L Ackler

Hongyu Zhao

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

Protein tyrosine phosphatase inhibitors and methods of use thereof

The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.

Synthetic route to anti-viral agents

The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R, R, R, R, R, A, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Modulators of 5-HT receptors and methods of use thereof

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Macrocyclic hepatitis C serine protease inhibitors

Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including cancer and Alzheimer's prevention and treatment. The compounds described herein can also treat memory loss. Also described herein are methods for producing macrolactones. The methods permit the high-yield synthesis of macrolactones in fewer steps and with a higher degree of substitution and specificity.

Bryostatin analogues and methods of making and using thereof

Growing community of inventors

Lake Bluff, IL, United States of America

Dennie S Welch